Kamran Ahmed, MD, H. Lee Moffitt Cancer Center, Tampa, FL, discusses the study design of the Phase II study (NCT03614949) of atezolizumab and stereotactic body radiation therapy (SBRT) and its potential as a treatment for metastatic, recurrent, or persistent cervical cancer. PD-L1 inhibitors have previously been approved for the treatment of cervical cancer, and SBRT is widely used in cervical cancer management. The prospective, non-randomized, open-label Phase II study is investigating the use of atezolizumab alongside SBRT in patients with metastatic, recurrent, or persistent cervical cancer, which is hypothesised to improve objective response rates compared to atezolizumab alone. Results of the initial 13 patients undergoing this treatment are presented as an interim analysis at the American Society for Radiation Oncology (ASTRO) 2022 Congress. This interview took place at the ASTRO 2022 Congress in San Antonio, Tx.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Research funding to the institution from Eli Lilly, Genentech, and BMS